NEW ORLEANSâ€”High remission rates with extended survival are being achieved in patients who had failed all other therapies â€” including allogeneic stem cell transplantation â€” for their acute lymphoblastic leukemia and otherwise had very short life expectancies. Stephan A Grupp, MD, PhD from the University of Pennsylvania and his colleague Michael Kalos PhD discussed their findings from a study presented here of T-cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) which they found to have significant in vivo proliferation, produce complete responses and had long-term persistence without graft versus host disease in children and adults with relapsed, refractory disease. Laurence Cooper MD, PhD, of the M D Anderson Cancer Center in Houston â€” moderator of a press briefing here on CAR T-cell therapy â€” assessed the potential scope of this treatment in hematologic malignancy and solid tumors. George Canellos MD from the Dana-Farber Cancer Institute in Boston added his opinion about the value and application of this technology.
You may also like...
The Smartest Oncologist In The World? 16 Apr, 2009 Higher Radiation Dose Improved Survival in Children with Ependymoma 12 May, 2015 Clear-cell renal cell cancer: first molecular prognostic marker also brings scope for drug targeting 27 Feb, 2014 Bevacizumab: New Standard for Non-Small Cell Lung Cancer? 16 Mar, 2008
- Previous story PDL1 inhibitor brings better responses in smokers with refractory lung cancer
- Next story HAND2 gene: key to endometrial, ovarian cancer detection and treatment individualisation
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014